BAKER BROS. ADVISORS LP Q3 2021 Filing
Filed November 15, 2021
Portfolio Value
$22.8B
Holdings
122
Report Date
Q3 2021
Filing Type
13F-HR
All Holdings (122 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 101 | HOOKGBPHOOKIPA Pharma Inc. | 700,481 | $4.1B | 18.12% | |
| 102 | 5E7Iteos Therapeutics, Inc. | 150,346 | $4.1B | 17.82% | |
| 103 | —Vincerx Pharma, Inc. | 241,379 | $3.9B | 17.14% | |
| 104 | XLRNAcceleron Pharma Inc. | 22,430 | $3.9B | 16.95% | |
| 105 | BNRBurning Rock Biotech Limited | 209,131 | $3.7B | 16.42% | |
| 106 | AKROAkero Therapeutics, Inc. | 118,378 | $2.6B | 11.62% | |
| 107 | —Gamida Cell Ltd. | 610,626 | $2.4B | 10.51% | |
| 108 | LPTXEURLeap Therapeutics, Inc. | 559,705 | $2.2B | 9.85% | |
| 109 | SERASera Prognostics, Inc. | 201,562 | $2.2B | 9.83% | |
| 110 | SNDXSyndax Pharmaceuticals, Inc. | 110,729 | $2.1B | 9.29% | |
| 111 | —LogicBio Therapeutics, Inc. | 451,478 | $2.1B | 9.08% | |
| 112 | —Evofem Biosciences, Inc. | 2,697,110 | $2.0B | 8.75% | |
| 113 | —TCR2 Therapeutics Inc. | 176,461 | $1.5B | 6.60% | |
| 114 | TARAProtara Therapeutics, Inc. | 199,671 | $1.4B | 6.07% | |
| 115 | INZYInozyme Pharma, Inc. | 106,999 | $1.2B | 5.45% | |
| 116 | KZRKezar Life Sciences, Inc. | 139,676 | $1.2B | 5.30% | |
| 117 | PASGPassage Bio, Inc. | 117,161 | $1.2B | 5.12% | |
| 118 | —Affimed N.V. | 164,605 | $1.0B | 4.47% | |
| 119 | SRZNWSurrozen, Inc. | 833,333 | $950.0M | 4.17% | |
| 120 | OYSTOyster Point Pharma, Inc. | 61,424 | $728.0M | 3.20% | |
| 121 | —Bellicum Pharmaceuticals, Inc. | 249,123 | $727.0M | 3.19% | |
| 122 | MREOMereo BioPharma Group plc | 292,692 | $708.0M | 3.11% |
PreviousPage 2 of 2